MNG702
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.491
- TNFA_SIGNALING_VIA_NFKB+0.375
- NOTCH_SIGNALING+0.336
- ESTROGEN_RESPONSE_EARLY+0.278
- UV_RESPONSE_UP+0.262
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.256
- APOPTOSIS+0.250
- MITOTIC_SPINDLE+0.230
- DNA_REPAIR+0.208
- ESTROGEN_RESPONSE_LATE+0.179
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.314
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.298
- ALLOGRAFT_REJECTION-0.255
- INTERFERON_GAMMA_RESPONSE-0.188
- KRAS_SIGNALING_UP-0.146
- SPERMATOGENESIS-0.105
- GLYCOLYSIS-0.103
- UV_RESPONSE_DN-0.073
- INTERFERON_ALPHA_RESPONSE-0.067
- ANGIOGENESIS-0.061
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1111 | — | — | 0.795 |
| 2 | MNG127 | — | — | 0.752 |
| 3 | MNG1051 | — | — | 0.678 |
| 4 | MNG1079 | — | — | 0.654 |
| 5 | MNG1104 | — | — | 0.605 |
| 6 | TCGA-CR-6491-01A-11R-1873-07 | — | — | 0.592 |
| 7 | MNG1013 | — | — | 0.589 |
| 8 | 9CD6C527-4E98-427F-9770-7155A1C6CB70 | — | — | 0.587 |
| 9 | MNG176 | — | — | 0.577 |
| 10 | MNG407 | — | — | 0.574 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.491 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.375 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.336 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.278 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.262 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.256 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.230 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.208 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.179 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.177 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.147 | Inavolisib | — uncovered |
| HYPOXIA | 0.146 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.144 | Temsirolimus | — uncovered |
| COAGULATION | 0.142 | Binimetinib | — uncovered |
| MYC_TARGETS_V2 | 0.139 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.126 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |